The North American human insulin drugs market is expected to register a CAGR of 4.41% during the forecast period of 2020 - 2025, and the market is estimated to reach a value of USD 12 billion by 2025. North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.
Key Market Trends
The United States Dominates the Market
Among the North American countries, the United States dominates around 94% of the total North America Human Insulin Drugs Market. This is mainly due to the high diabetes prevalence in the country. The United States records the highest healthcare expenditure globally, and it also has a higher adoption of advanced therapeutics. The market size of the insulin market in 2017 was USD 10.6 billion, and the market is expected to record a CAGR of 4.29% during the forecast period (2020 - 2025). Moreover, the United States accounts for the highest sales of the long-acting insulin, Lantus, across the North America Region. The majority of diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the US market.
Humalog holds Highest Market Share in 2019.
Humalog occupied the largest market share in 2019. However, the product is expected to decrease during the forecast period, due to similar insulin glargine present in the market, like FIASP and Admelog. Admelog is proven to lower A1C similar to Humalog. Admelog is available in the Admelog SoloStar pen or a vial and can be used in a pump. In March 2019, Eli Lilly launched the authorized generic of its insulin lispro injection (Humalog) in the United States. The new generic Humalog has a list price 50% lower than the Humalog list price existing in the market.
The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. While in the remaining countries, the manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies to strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support